Third Harmonic Bio ( NASDAQ: THRD) will be liquidating the company and selling its remaining assets, the company said on ...

Third Harmonic Bio Inc (NASDAQ:THRD) shares are soaring on Monday after the company announced a plan of liquidation and dissolution.

Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution ...

San Francisco, USA-based inflammatory disease biotech Third Harmonic Bio (Nasdaq: THRD) saw its shares rocket almost 40% to $5.09 as the company revealed an orderly exit plan.

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing ...

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

On Monday, Raymond James maintained a Market Perform rating on Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), following the company’s announcement of a liquidation and dissolution plan.

Third Harmonic Bio (NASDAQ:THRD) will be liquidating the company and selling its remaining assets, the company said on Monday. The California-based pharma company will be selling its assets ...

SAN FRANCISCO - Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company with a current market capitalization of $164.18 million, has announced its board of directors ...

Shares of Third Harmonic Bio, Inc. (THRD) drew investor attention on Monday after the company announced that its board of ...